Market Cap 549.78B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 21.83
Forward PE 19.74
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 8,518,349
Avg Vol 8,017,376
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 27%
Beta 0.26
Analysts Strong Sell
Price Target $260.46

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
cwEWF
cwEWF Jun. 23 at 10:23 AM
$JNJ favors rally in 5 of (1) after appears ended 4 at 227.5 low. As long as it holds above 6.01.2026 low, it can see more upside in proposed outlook targeting 259.3 or higher #Elliottwave #JNJ
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 23 at 3:59 AM
$BMY $PFE $SLS $JNJ 4. My # 1 Suitor for Sellas remains Pfizer followed by close 2nd $BMY 3rd $ABBV and 4Th $JNJ ✌️🙏❤️‍🩹 While Pfizer has made all the right moves in preparation of Sellas BO in January 2026 Pfizer appointed Michael Burns brother of SLS CFO John Burns as Senior Medical Director of Oncology Late Development, coming directly from oncology early development at AbbVie. Someone who spent their career in the belly of the beast understanding exactly how AbbVie develops oncology assets, exactly where the gaps in the Venetoclax franchise are, and exactly what kind of validated late stage asset Pfizer needs to compete in hematologic malignancies just walked through Pfizer's door. Dr. Angelos Stergiou has directly called out Unlike Onureg, GPS does not suppress the bone marrow. This is a critical advantage for AML patients who already have fragile blood counts. AbbVie will be the biggest looser and Ventoclax will be Obsolete. JNJ BOD Katherine Bach connection is compelling. P1 ✌️🙏❤️‍🩹
1 · Reply
Sak12345
Sak12345 Jun. 23 at 1:56 AM
$JNJ "BREAKING NEWS CLARITY ACT TO BE PASSED THIS WEEK" https://www.youtube.com/live/OytRzE66YYw?is=12wSXXX33pAdmXOJ JNJ
0 · Reply
dewmoore
dewmoore Jun. 23 at 1:13 AM
$PFE paid $43B for Seagen in 2023 just to watch their main ADC flop TONIGHT after hours, opening the door for SLS. If $SLS captures even half of that value at $20B, with their 196.6M share count that puts the stock price over $101. At $20 Billion Valuation: $101.71 per share At $40 Billion Valuation: $203.42 per share $PFE CEO is NOW desperate AF for a lifeline, while $MRK $JNJ $LLY jump in the fight for oncology dominance. A massive bidding war is gearing up, though $SLS could easily go it alone with blockbuster patents expiring everywhere in 2027 and 2028. Throw in High Cost to Borrow (CTB) flagging a short squeeze BEFORE we get the 80th even happens.....Hold on to your hats this shit is gonna be crrraazzzzzy. 💣🚀
2 · Reply
Pearl_Power
Pearl_Power Jun. 22 at 8:01 PM
$JNJ $AMGN long both
0 · Reply
DidYouReadThis
DidYouReadThis Jun. 22 at 6:19 PM
$OTLK How many opthalmic bevacizumab injections do you anticipate over 12 years combining USA and internationally? $REGN $JNJ $ALC
1 · Reply
briefingcom
briefingcom Jun. 22 at 3:21 PM
$ABBV: AbbVie is trading higher after agreeing to buy Apogee Therapeutics for $135.11/share in cash, valuing $APGE at about $10.9 bln. The deal deepens ABBV’s immunology pipeline, but investors will be watching the price tag, clinical risk, and long path to EPS accretion. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/22/abbvie-catches-apogee-fever-109b-deal-expands-immunology-and-asthma-pipeline?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link $APOG #Abbvie $LLY $JNJ #Apogee #biotech #pharma #Immunology #asthma #healthcare #health
0 · Reply
TradeVestor
TradeVestor Jun. 22 at 12:37 PM
So dam sick of these damn chip/semi/AI stocks going up for what feels like forever. I am rage holding $SOXS for revenge lol (just got in) and $DOCU for software recovery. Plus my cushy, safe-haven stocks $MO $KO $JNJ and more for when sanity returns and safety is sought.
1 · Reply
DailyWatcher_
DailyWatcher_ Jun. 21 at 7:50 PM
3 Dividend / Cash-Flow Stocks I Like Right Now Not chasing hype here — just steady businesses that generate real cash. $UNH — Healthcare leader, recently under pressure, but long-term demand trend is still intact $BLK — Global asset management giant, benefits from long-term ETF and passive flow growth $QCOM — Quiet compounder powering mobile, edge, and connected devices globally $MSFT — Strong dividend growth + AI/cloud cash engine, still one of the highest-quality names in tech $JNJ — Defensive healthcare staple with decades of consistent dividend increases What they all have in common: Strong cash flow, long operating history, and consistent shareholder returns. Not exciting every day — but that’s the point. Sometimes the best returns come from quality businesses you can actually hold through cycles. Next alert is coming soon. Turn on notifications so you don’t miss early moves — otherwise you’ll likely see the move after it already happened.
0 · Reply
cea
cea Jun. 21 at 4:09 PM
$SLS Based on these comments…probably not. It appears $JNJ wants to pay exorbitant prices for incomplete work and do it all themselves. Rather short sighted from a strategic perspective. I’m not taking $JNJ off my list of contenders, but it seems they don’t want to be a real leader in the oncology space…and that is OK…plenty of other players will want a unicorn portfolio in the AML space.
0 · Reply
Latest News on JNJ
Johnson & Johnson presents first results from ENERGY study

2026-06-11T09:26:54.000Z - 12 days ago

Johnson & Johnson presents first results from ENERGY study


Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 14 days ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion


Johnson & Johnson to acquire Firefly Bio for $1B in cash

2026-06-08T12:14:56.000Z - 15 days ago

Johnson & Johnson to acquire Firefly Bio for $1B in cash


Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 15 days ago

Johnson & Johnson to buy Firefly Bio for $1 billion


Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 4 weeks ago

Johnson & Johnson says nipocalimab approved in China


CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 6 weeks ago

CVS to drop J&J's Stelara from its main formularies

CVS


J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 7 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine


Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 7 weeks ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM


J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 2 months ago

J&J sees AI halving the time to generate drug development leads


Johnson & Johnson Transcript: AGM 2026

Apr 23, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: AGM 2026


cwEWF
cwEWF Jun. 23 at 10:23 AM
$JNJ favors rally in 5 of (1) after appears ended 4 at 227.5 low. As long as it holds above 6.01.2026 low, it can see more upside in proposed outlook targeting 259.3 or higher #Elliottwave #JNJ
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 23 at 3:59 AM
$BMY $PFE $SLS $JNJ 4. My # 1 Suitor for Sellas remains Pfizer followed by close 2nd $BMY 3rd $ABBV and 4Th $JNJ ✌️🙏❤️‍🩹 While Pfizer has made all the right moves in preparation of Sellas BO in January 2026 Pfizer appointed Michael Burns brother of SLS CFO John Burns as Senior Medical Director of Oncology Late Development, coming directly from oncology early development at AbbVie. Someone who spent their career in the belly of the beast understanding exactly how AbbVie develops oncology assets, exactly where the gaps in the Venetoclax franchise are, and exactly what kind of validated late stage asset Pfizer needs to compete in hematologic malignancies just walked through Pfizer's door. Dr. Angelos Stergiou has directly called out Unlike Onureg, GPS does not suppress the bone marrow. This is a critical advantage for AML patients who already have fragile blood counts. AbbVie will be the biggest looser and Ventoclax will be Obsolete. JNJ BOD Katherine Bach connection is compelling. P1 ✌️🙏❤️‍🩹
1 · Reply
Sak12345
Sak12345 Jun. 23 at 1:56 AM
$JNJ "BREAKING NEWS CLARITY ACT TO BE PASSED THIS WEEK" https://www.youtube.com/live/OytRzE66YYw?is=12wSXXX33pAdmXOJ JNJ
0 · Reply
dewmoore
dewmoore Jun. 23 at 1:13 AM
$PFE paid $43B for Seagen in 2023 just to watch their main ADC flop TONIGHT after hours, opening the door for SLS. If $SLS captures even half of that value at $20B, with their 196.6M share count that puts the stock price over $101. At $20 Billion Valuation: $101.71 per share At $40 Billion Valuation: $203.42 per share $PFE CEO is NOW desperate AF for a lifeline, while $MRK $JNJ $LLY jump in the fight for oncology dominance. A massive bidding war is gearing up, though $SLS could easily go it alone with blockbuster patents expiring everywhere in 2027 and 2028. Throw in High Cost to Borrow (CTB) flagging a short squeeze BEFORE we get the 80th even happens.....Hold on to your hats this shit is gonna be crrraazzzzzy. 💣🚀
2 · Reply
Pearl_Power
Pearl_Power Jun. 22 at 8:01 PM
$JNJ $AMGN long both
0 · Reply
DidYouReadThis
DidYouReadThis Jun. 22 at 6:19 PM
$OTLK How many opthalmic bevacizumab injections do you anticipate over 12 years combining USA and internationally? $REGN $JNJ $ALC
1 · Reply
briefingcom
briefingcom Jun. 22 at 3:21 PM
$ABBV: AbbVie is trading higher after agreeing to buy Apogee Therapeutics for $135.11/share in cash, valuing $APGE at about $10.9 bln. The deal deepens ABBV’s immunology pipeline, but investors will be watching the price tag, clinical risk, and long path to EPS accretion. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/22/abbvie-catches-apogee-fever-109b-deal-expands-immunology-and-asthma-pipeline?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link $APOG #Abbvie $LLY $JNJ #Apogee #biotech #pharma #Immunology #asthma #healthcare #health
0 · Reply
TradeVestor
TradeVestor Jun. 22 at 12:37 PM
So dam sick of these damn chip/semi/AI stocks going up for what feels like forever. I am rage holding $SOXS for revenge lol (just got in) and $DOCU for software recovery. Plus my cushy, safe-haven stocks $MO $KO $JNJ and more for when sanity returns and safety is sought.
1 · Reply
DailyWatcher_
DailyWatcher_ Jun. 21 at 7:50 PM
3 Dividend / Cash-Flow Stocks I Like Right Now Not chasing hype here — just steady businesses that generate real cash. $UNH — Healthcare leader, recently under pressure, but long-term demand trend is still intact $BLK — Global asset management giant, benefits from long-term ETF and passive flow growth $QCOM — Quiet compounder powering mobile, edge, and connected devices globally $MSFT — Strong dividend growth + AI/cloud cash engine, still one of the highest-quality names in tech $JNJ — Defensive healthcare staple with decades of consistent dividend increases What they all have in common: Strong cash flow, long operating history, and consistent shareholder returns. Not exciting every day — but that’s the point. Sometimes the best returns come from quality businesses you can actually hold through cycles. Next alert is coming soon. Turn on notifications so you don’t miss early moves — otherwise you’ll likely see the move after it already happened.
0 · Reply
cea
cea Jun. 21 at 4:09 PM
$SLS Based on these comments…probably not. It appears $JNJ wants to pay exorbitant prices for incomplete work and do it all themselves. Rather short sighted from a strategic perspective. I’m not taking $JNJ off my list of contenders, but it seems they don’t want to be a real leader in the oncology space…and that is OK…plenty of other players will want a unicorn portfolio in the AML space.
0 · Reply
kiwiSurfer
kiwiSurfer Jun. 21 at 3:19 PM
$LEGN $JNJ will not get outbid fot $LEGN but won’t put it past $NVS ot $LLY getting into a bidding war for $LEGN just to make it more expensive for their competitor $JNJ
1 · Reply
biolover
biolover Jun. 21 at 1:29 PM
As I discussed below $RVMD MGT enjoys leaking BD discussions. As significant as Daraxonrasib impact on pancreatic and other cancers .. it does help MC to have a vocal management .. I admire RVMD and was in it for years but I see more upside at this point for underdogs that have better molecules $ERAS or related $TNGX Although pharma that don’t have vision of what will be dominant in this space at 2032 could pull > $40 B deal. Examples $JNJ and MRK .. we need CEOs of suppressed biotechs such as $VKTX to engage more abs be more vocal like RVMD CEO
3 · Reply
cb5000calls
cb5000calls Jun. 20 at 11:02 PM
🚨 $SLS BIDDING WAR WATCH 🚨 If the reports are true and Abbvie is about to drop ~$11 BILLION on Appogeee then one major bidder may have just exited the field. 👀 But here’s the bigger takeaway… Big Pharma is STILL spending aggressively. Patent cliffs are coming. Pipelines need replenished. Oncology remains one of the hottest M&A sectors on the planet. So who is left? 💥 $MRK 💥 $PFE 💥 $JNJ Meanwhile: ✅ REGAL still hasn’t reached Event #80 ✅ FDA approved unlimited dosing ✅ GPS continues running far beyond expectations ✅ Shorts remain trapped ✅ Cash runway removes financing fears The question isn’t whether Big Pharma is buying assets… The question is who wants GPS first. 🔥🚀 #AML #Cancer #Biotech #MergersAndAcquisitions
2 · Reply
wwmeinc
wwmeinc Jun. 19 at 1:31 PM
$VKTX $PFE $LLY $MRK $JNJ Not as if that 'horse' has not already left the barn...just saying...shareholders want ROE.....mgmt wants bonuses...the two go hand in hand with lower Chinese dev. costs...maybe losser reg. costs as well....Wonder which mega-drug firm was lobbying for the good GOP House Rep. to bring this forward now???? glta https://chinaselectcommittee.house.gov/media/letters/moolenaar-calls-to-restrict-american-investment-in-china-s-biotechnology-companies
1 · Reply
Orchard
Orchard Jun. 19 at 11:33 AM
$MRNA $JNJ $PFE Wow! Tulsi drops the bomb on the Covid lies. And morons still believe Big Pharma would never hide adverse effect from a “gene therapy” But 5 years ago I was the conspiracy theorists. Every day more vindication. I trust Strip Club operator $RICK more than these drug firms. How’s that safe Oxy working out? That asbestos baby powder, cancer causing sunscreen…..
2 · Reply
Orchard
Orchard Jun. 18 at 7:53 PM
$MRNA Jesus the levels of trust in pharma is off the charts here. It is and never was a vaccine. Screenshot this morons. They had to LEGALLY change the definition so the public would take it because it is a GENE therapy. $JNJ can’t even make baby powder w/o asbestos or sunscreen w/o cancer causing chemicals and you trust their “studies” Trust an honest strip club operation $RICK more than anything pharma says.
1 · Reply
PittsburghTrader
PittsburghTrader Jun. 18 at 7:12 PM
$JNJ thought might try to recover back > $230 into the close but guess not
0 · Reply
Orchard
Orchard Jun. 18 at 6:24 PM
$MRNA The Covid Vaxx “gene therapy” has shown these companies will bury adverse effect data like $JNJ $PFE to seal the records for 55 yrs. Remember this companies poisoned people as they were NEVER 100% safe and effective. My friend literally went blind in his right eye from their unneeded “cure”. Trust the Strip Club $RICK before I’d ever let them inject me or my child with essentially was the largest medical experiment with the world as it’s Guinea pigs
3 · Reply
Bazziggr
Bazziggr Jun. 18 at 4:54 PM
$JNJ & BSX
0 · Reply
PittsburghTrader
PittsburghTrader Jun. 18 at 4:18 PM
$JNJ wow, just b/c $QQQ rallying gets this kind of pullback?
0 · Reply
Estimize
Estimize Jun. 18 at 2:15 PM
Wall St is expecting 2.85 EPS for $JNJ Q2 [Reporting 07/15 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont
0 · Reply
Quantumup
Quantumup Jun. 18 at 10:24 AM
BofA🏁 $IMMX and said: We initiate coverage of IMMX with a Buy rating and $27 PO. $PRTA $JNJ - GMAB ABBV REGN AZN BofA added: IMMX is developing NXC201 for AL amyloidosis, a rare disease with damaged vital organs and no approved treatments. Early data of NXC-201 shows ~95% complete response and rapid minimal residual disease in relapsed/refractory (r/r) AL amyloidosis. The safety profile was favorable for patients facing potential organ failure with no observed neurotoxicity. Updated phase 2 data is expected in late September, and 1-year follow-up data is expected in 1Q27 to support a potential BLA submission in 1H27. If approved, we think a clinical profile with deep and rapid response and tolerability could be key for adoption.
0 · Reply